“Olaparib-Resistant Ovarian Cancer Treatment: Combining with ATR/CHK1 Inhibitors”

https://pubmed.ncbi.nlm.nih.gov/38114660

The study found that combining olaparib with ATR/CHK1 inhibitors enhances cytotoxic activity in olaparib-resistant ovarian cancer cells with BRCA2 reversion mutation, alters DNA damage response protein expression, and abrogates olaparib-induced upregulation of proteins determining cell fate after DNA damage.